Literature DB >> 2477457

HIV promoter activity in primary antigen-specific human T lymphocytes.

R T Horvat1, C Wood.   

Abstract

Human retroviruses, such as the HIV, infects human T cells, and efficient HIV replication occurs primarily in activated T cells rather than resting cells. Increased HIV production is likely caused by the activation of the retroviral promoter, and the HIV promoter may be regulated by intracellular signals induced during immune stimulation. To examine the regulation of retroviral promoter activity in normal, Ag-specific primary T lymphoblasts, a heterogeneous population of primary human T cells was transfected with either the HIV promoter or a promoter from a different retrovirus, Rous sarcoma virus (RSV) by protoplast fusion technique. Transfected T cells responded normally to Ag or mitogen stimulation, and activation of these T cells increased both the HIV and RSV promoter activity. Promoter activity was assessed by using transient expression assays after the T cells were restimulated with Ag, mitogen, or IL-2. In situ hybridization of transfected human T cells showed that 68 to 95% of activated lymphocytes expressed CAT mRNA directed by HIV or RSV. Thus, protoplast transfection of primary T cells was efficient in that the majority of cells expressed CAT message. By deletion of different regions of the HIV promoter, the enhancer region was identified as necessary for effective HIV promoter activity. In addition these deletion studies identified a region that negatively affects HIV promoter activity in primary T cells. Cotransfection of the HIV promoter with the HIV transactivator protein, tat, increases HIV promoter activity in both resting and activated primary human T cells only when the tat target sequences were present.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2477457

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Cyclin T1 expression is mediated by a complex and constitutively active promoter and does not limit human immunodeficiency virus type 1 Tat function in unstimulated primary lymphocytes.

Authors:  Juan Martin-Serrano; Kelvin Li; Paul D Bieniasz
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

2.  Stimulation of a human T-cell clone with anti-CD3 or tumor necrosis factor induces NF-kappa B translocation but not human immunodeficiency virus 1 enhancer-dependent transcription.

Authors:  U Hazan; D Thomas; J Alcami; F Bachelerie; N Israel; H Yssel; J L Virelizier; F Arenzana-Seisdedos
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

3.  Differential activation of human immunodeficiency virus type 1 and 2 transcription by specific T-cell activation signals.

Authors:  M C Hannibal; D M Markovitz; N Clark; G J Nabel
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

4.  Identification and characterization of the bovine immunodeficiency-like virus tat gene.

Authors:  Z Q Liu; D Sheridan; C Wood
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

5.  Transactivation of the human immunodeficiency virus promoter by human herpesvirus 6 (HHV-6) strains GS and Z-29 in primary human T lymphocytes and identification of transactivating HHV-6(GS) gene fragments.

Authors:  R T Horvat; C Wood; S F Josephs; N Balachandran
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

6.  Phosphatidylcholine hydrolysis activates NF-kappa B and increases human immunodeficiency virus replication in human monocytes and T lymphocytes.

Authors:  F Arenzana-Seisdedos; B Fernandez; I Dominguez; J M Jacqué; D Thomas; M T Diaz-Meco; J Moscat; J L Virelizier
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

7.  Identification and characterization of a human herpesvirus 6 gene segment that trans activates the human immunodeficiency virus type 1 promoter.

Authors:  Y Q Geng; B Chandran; S F Josephs; C Wood
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

Review 8.  Interleukin-2 and human immunodeficiency virus infection: pathogenic mechanisms and potential for immunologic enhancement.

Authors:  A Kinter; A S Fauci
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.